Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : This week    source : Www.biospace.com    save search
BioMarin Reports Record Financial Results for the First Quarter 2024
Published: 2024-04-24 (Crawled : 00:00) - biospace.com/
BMRN | $91.25 -0.88% -0.89% 1.6M twitter stocktwits trandingview |
Health Technology
 | | O: 0.08% H: 0.0% C: 0.0%
first for financial results
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
Published: 2024-04-24 (Crawled : 23:00) - biospace.com/
ARWR | $23.285 -2.08% -2.13% 810K twitter stocktwits trandingview |
Health Technology
 | | O: -0.76% H: 0.0% C: 0.0%
pharmaceuticals results
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
Published: 2024-04-24 (Crawled : 22:00) - biospace.com/
PLSE | $6.86 0.0% 130K twitter stocktwits trandingview |
Health Technology
 | | O: -2.11% H: 0.0% C: 0.0%
first conference for financial results
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
Published: 2024-04-24 (Crawled : 22:00) - biospace.com/
RCUS 4 | $15.43 -0.45% 0.0% 520K twitter stocktwits trandingview |
Health Technology
 | | O: -3.26% H: 0.0% C: 0.0%
asco arcus meeting
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Published: 2024-04-24 (Crawled : 21:00) - biospace.com/
ACAD | News | $16.57 -1.02% -1.03% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.06% H: 0.0% C: 0.0%
first pharmaceuticals financial results
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
Published: 2024-04-24 (Crawled : 19:00) - biospace.com/
PGEN | $1.42 1.43% 1.41% 560K twitter stocktwits trandingview |
Health Technology
 | | O: -0.36% H: 0.0% C: 0.0%
prgn-2012 respiratory asco treatment immunotherapy for meeting study
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Published: 2024-04-24 (Crawled : 19:00) - biospace.com/
NVCR | $12.35 2.45% 2.39% 1.1M twitter stocktwits trandingview |
Health Technology
 | | O: -0.25% H: 0.0% C: 0.0%
lung asco cancer cell for trial results
NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024
Published: 2024-04-24 (Crawled : 18:00) - biospace.com/
NAOV 4 | $0.77 -5.68% 8.6K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
microcap
First Approval for Rare Pediatric Cancer; New OTC Opioid Overdose Option
Published: 2024-04-24 (Crawled : 16:00) - biospace.com/
ABT | News | $106.89 -0.65% -0.22% 5.1M twitter stocktwits trandingview |
Health Technology
 | | O: -1.04% H: 0.0% C: 0.0%
PRGO | $31.23 2.43% 0.0% 960K twitter stocktwits trandingview |
Health Technology
 | | O: 0.1% H: 0.0% C: 0.0%
JNJ | News | $148.53 -0.69% -0.14% 9.6M twitter stocktwits trandingview |
Health Technology
 | | O: -1.02% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.82% H: 0.0% C: 0.0%
rare first opioid approval for
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Published: 2024-04-24 (Crawled : 15:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M twitter stocktwits trandingview |
Health Technology
 | | O: -1.02% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.82% H: 0.0% C: 0.0%
CVAC | $2.51 -3.46% -3.59% 1.1M twitter stocktwits trandingview |
Health Technology
 | | O: -5.77% H: 0.0% C: 0.0%
business
BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior ExchangeStrategic Audit Completion Set to Enhance BioStem Technologies' Market Position and Shareholder Value
Published: 2024-04-24 (Crawled : 15:00) - biospace.com/
BSEM | $9.24 -38.71% 32K twitter stocktwits trandingview |
n/a
 | Email alert Add to watchlist
for set market
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
SNPX | $4.6 0.66% 0.65% 14K twitter stocktwits trandingview |
Professional, Scientific, and T...
 | | O: -0.44% H: 0.0% C: 0.0%
nasdaq for
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.82% H: 0.0% C: 0.0%
LTRN | News | $5.44 -5.72% -6.07% 96K twitter stocktwits trandingview |
Health Technology
 | | O: 2.77% H: 0.0% C: 0.0%
pharma drug key leaders development
GoodRx Announces Date for 2024 Investor Day
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
GDRX 4 | $6.96 -0.14% -0.14% 610K twitter stocktwits trandingview |
Technology Services
 | | O: 5.64% H: 0.0% C: 0.0%
day for
United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
UTHR | $237.06 1.11% 1.09% 610K twitter stocktwits trandingview |
Health Technology
 | | O: -0.7% H: 0.0% C: 0.0%
first therapeutics
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
KRBP | $2.64 -90.21% 360 twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
first favorable biopharma trial
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
NBIX | News 4 | $138.91 -0.84% -0.85% 880K twitter stocktwits trandingview |
Health Technology
 | | O: 0.83% H: 0.0% C: 0.0%
initiative
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
CVAC | $2.51 -3.46% -3.59% 1.1M twitter stocktwits trandingview |
Health Technology
 | | O: -5.77% H: 0.0% C: 0.0%
start influenza collaboration development study
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
BIAF | $2.4 -7.34% -7.92% 110K twitter stocktwits trandingview |
| | O: -7.34% H: 0.0% C: 0.0%
development growth
Valcare Medical, Inc. Announces Corporate Restructuring and Appointment of New CEO
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
WEGZY | $7.47 -0.12% 50K twitter stocktwits trandingview |
Manufacturing
 | Email alert Add to watchlist
ceo
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M twitter stocktwits trandingview |
Consumer Services
BOF | $1.99 70.09% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.51 6.03% 40.62% 1.7M twitter stocktwits trandingview |

LICN | $0.941 68.04% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.31 65.5% 39.58% 70M twitter stocktwits trandingview |
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M twitter stocktwits trandingview |
Technology Services
WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services
AIH | $0.45 12.5% 30.92% 320K twitter stocktwits trandingview |
Health Services
MULN | News | $3.78 38.46% 27.78% 13M twitter stocktwits trandingview |
Information
RILY | $29.86 37.48% 27.26% 12M twitter stocktwits trandingview |
Finance
Your saved searches
Save your searches and get alerts when important news are released.